U.S. market Closed. Opens in 2 days 2 hours 54 minutes

ESPR | Esperion Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for ESPR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (7%)

Company Industry
P/E Ratio (TTM) -4.08 16.80
PEG Ratio (TTM) -0.30 -22.35
P/S Ratio (TTM) 1.50 5.40
P/B Ratio (TTM) -1.17 4.32
P/FCF Ratio (TTM) -42.18 8.04
Price to 5YR AVG Earnings Ratio -0.39 28.14
Price to 5YR AVG FCF Ratio -2.81 21.09

Profitability (35%)

Company Industry
ROA (TTM) -27.96% 2.55%
ROE (TTM) 26.20% 17.61%
Net Profit Margin (TTM) -35.46% -13.06%
ROIC 5YR AVG 19.06% 9.72%

Growth (23%)

4QTR AVG 3YR AVG 5YR AVG
EPS -8.81% -28.71% 5.55%
Revenue 76.84% -10.58% 3.72%
Net Income -3.09% -32.77% -12.26%
Cash Flow 15.51% -59.38% -24.38%

Health (14%)

Company Industry
Current Ratio (TTM) 1.97 2.49
Quick Ratio (TTM) 1.49 1.85
D/E Ratio (TTM) -1.61 -0.28
Interest Coverage (TTM) -20.70 11.92
Piotroski F-Score 2 6
Altman Z-Score N/A 4.64
LTL to 5YR AVG FCF -3.37 4.63
Shares Outstanding Growth 5YR AVG 38.58% 29.96%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙